Information:
Fel:
ID
14617
Beskrivning
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00005947
Länk
https://clinicaltrials.gov/show/NCT00005947
Nyckelord
Versioner (1)
- 2016-04-24 2016-04-24 -
Uppladdad den
24 april 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Prostate Cancer NCT00005947
Eligibility Prostate Cancer NCT00005947
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT00005947
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Metastatic prostate cancer
Item
metastatic disease as evidenced by soft tissue and/or bony metastases.
boolean
C0936223 (UMLS CUI [1])
PSA measurement
Item
baseline psa value of at least 5 ng/ml. all subjects must have stable or rising psa.
boolean
C0201544 (UMLS CUI [1])
Tumor progression after hormonal therapy
Item
tumor progression after hormonal therapy.
boolean
C0178874 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
C0279025 (UMLS CUI [1,2])
Hormone therapy: specification
Item
hormonal therapy consisting of castration by orchiectomy or lhrh agonists for treatment of prostate cancer. castration levels of testosterone (< 50 ng/dl) must be documented for all subjects including subjects who underwent orchiectomy as therapy for cancer of the prostate.
boolean
C0029189 (UMLS CUI [1])
C1518041 (UMLS CUI [2])
C0202227 (UMLS CUI [3])
C1518041 (UMLS CUI [2])
C0202227 (UMLS CUI [3])
Antiandrogen therapy
Item
a subject is eligible if he initially responded to antiandrogen withdrawal (> 25% decrease in psa) but at the time of registration demonstrated tumor progression. a subject is eligible if he failed to respond to antiandrogen withdrawal.
boolean
C0002842 (UMLS CUI [1,1])
C0683154 (UMLS CUI [1,2])
C0683154 (UMLS CUI [1,2])
Cancer-related pain and analgesics
Item
subjects have no cancer-related pain and do not regularly require analgesics for cancer-related pain.
boolean
C1719395 (UMLS CUI [1])
C0002771 (UMLS CUI [2])
C0002771 (UMLS CUI [2])
ECOG performance status
Item
ecog performance status of 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Life expectancy
Item
life expectancy of at least 16 weeks.
boolean
C0023671 (UMLS CUI [1])
Hematologic, renal, and liver function
Item
adequate hematologic, renal, and liver function.
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Exclusion criteria
Item
exclusion criteria include:
boolean
C0680251 (UMLS CUI [1])
Visceral organ metastases and effusions
Item
visceral organ metastases (e.g., liver, lung, brain) or cytologically positive effusions (e.g., pleural effusions or ascites).
boolean
C0027627 (UMLS CUI [1,1])
C0442045 (UMLS CUI [1,2])
C0013687 (UMLS CUI [2])
C0442045 (UMLS CUI [1,2])
C0013687 (UMLS CUI [2])
Metastatic disease need radiotherapy
Item
metastatic disease expected to be in need of radiation therapy within 4 months.
boolean
C0027627 (UMLS CUI [1,1])
C1522449 (UMLS CUI [1,2])
C1522449 (UMLS CUI [1,2])
Experimental drugs
Item
concurrent therapy with experimental agents.
boolean
C0304229 (UMLS CUI [1])
Systemic corticosteroids daily dose
Item
systemic corticosteroids at doses greater than 40 mg hydrocortisone per day for any reason other than treatment of prostate cancer within the previous 6 months without prior approval.
boolean
C2825233 (UMLS CUI [1,1])
C2348070 (UMLS CUI [1,2])
C2348070 (UMLS CUI [1,2])
Eligibility criteria
Item
please note that there are additional eligibility criteria. the study center will determine if you meet all of the criteria.
boolean
C1516637 (UMLS CUI [1])